Providence St. Jude Medical Center
Fullerton, California 92835
7 studies enrolling now · 12 studies all time
What they study most
Advanced Breast Cancer, Advanced Ovarian Cancer, Advanced Solid Tumor, Advanced/Metastatic Non-Small Cell Lung Cancer, Breast Cancer, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Cerebral Stroke, Endometrioid Ovarian Cancer, Epithelial Ovarian Cancer, FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancer
Studies at this site
- A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer — Recruiting now
- A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) — Recruiting now
- Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers — Recruiting now
- CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer — Recruiting now
- A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors — Recruiting now
- CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. — Recruiting now
- Telerehabilitation Early After Stroke — Recruiting now
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Running, not enrolling
- A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer — Running, not enrolling
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease — Running, not enrolling
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Running, not enrolling
- First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer — Running, not enrolling